Related references
Note: Only part of the references are listed.Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2023)
Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma
Gilbert Youssef et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2022)
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
Ingo K. Mellinghoff et al.
CLINICAL CANCER RESEARCH (2021)
Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study
Kaspar Draaisma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment
Raymond Y. Huang et al.
NEURO-ONCOLOGY (2020)
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma
Ingo K. Mellinghoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials
Maryam Moradi Binabaj et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2018)
Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma
Jacob J. Mandel et al.
NEURO-ONCOLOGY (2018)
Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome
Aikaterini Kotrotsou et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients
Nova F. Smedley et al.
SCIENTIFIC REPORTS (2018)
Distinct Phenotypic Clusters of Glioblastoma Growth and Response Kinetics Predict Survival
Corbin A. Rayfield et al.
JCO CLINICAL CANCER INFORMATICS (2018)
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single- and multicenter trials
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2017)
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Benjamin M. Ellingson et al.
NEUROTHERAPEUTICS (2017)
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Contrast-Enhancing Tumor Growth Dynamics of Preoperative, Treatment-Naive Human Glioblastoma
Benjamin M. Ellingson et al.
CANCER (2016)
AVAREG: a phase 2, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma
Alba A. Brandes et al.
NEURO-ONCOLOGY (2016)
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Michael Weller et al.
CLINICAL CANCER RESEARCH (2015)
Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma
Benjamin M. Ellingson et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Patient and treatment factors associated with survival among adult glioblastoma patients: A USA population-based study from 2000-2010
I-Wen Pan et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2015)
Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial
Benjamin M. Ellingson et al.
RADIOLOGY (2014)
Extent of resection and radiotherapy in GBM: A 1973 to 2007 surveillance, epidemiology and end results analysis of 21,783 patients
Pascal O. Zinn et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Improved survival time trends for glioblastoma using the SEER 17 population-based registries
Matthew Koshy et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Glioblastoma survival in the United States before and during the temozolomide era
Derek R. Johnson et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004
Luc Bauchet et al.
NEURO-ONCOLOGY (2010)
Independent association of extent of resection with survival in patients with malignant brain astrocytoma
Matthew J. McGirt et al.
JOURNAL OF NEUROSURGERY (2009)
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Dieto Brandsma et al.
LANCET ONCOLOGY (2008)
A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle
K. R. Swanson et al.
BRITISH JOURNAL OF CANCER (2008)
Share Paper
